Ozenoxacin is a nonfluorinated quinolone antibacterial, which shows potent activities against the main microorganisms isolated from skin and soft tissue infections.
Ozenoxacin (OZN) shows potent antibacterial activities against clinical isolates of Gram-positive microorganisms, with MICs ranging from 0.008 to 4 mg/L. Ozenoxacin shows good activities against strains of MRSA, MSSA, MSSE, and MRSE with 2, 3, or 4 mutations in the gyrA and grlA (parC) genes[1]. Ozenoxacin inhibits MSSA strains and S. agalactiae strains, with the rates of resistance of >10-10 and 5.3 × 10-10, respectively. The maximum MIC value for mutant strains is 8 mg/L for ozenoxacin[2].
[1]. López Y, et al. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria. Antimicrob Agents Chemother. 2013 Dec;57(12):6389-92. [2]. López Y, et al. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci. J Antimicrob Chemother. 2015 Jan;70(1):57-61